Document ID: chunk:federal_register_of_legislation:F2006L02853:body:0:p6
Version: federal_register_of_legislation:F2006L02853
Segment Type: other
Provision Reference: 
Character Range: 15245–18542

merit criterion, applicants could address the following factors:

            (a) the extent to which the proposed activities involve leading edge technologies, techniques or skills;

            (b) the degree of innovation evident in the proposed activities;

            (c) whether the proposed activities include activity that is new and different for the applicant in Australia;

            (d) the extent to which the proposed activities are world class in nature;

            (e) the level of technical risk associated with the proposed activities, and the robustness of strategies to manage that risk; and

            (f) whether the research is conducted to global good laboratory, clinical and manufacturing practice standards.

    These factors should not be considered exhaustive nor will they all be applicable to all applicants.  Applicants are also welcome to provide further relevant evidence to support their claims under this merit criterion.
    Criterion 4: Level of Benefit to the Australian Economy
    The Board/Committee will assess the level of benefit to the Australian economy from the eligible Australian pharmaceutical R&D activities proposed by each applicant, including the contribution to the sustainability of an internationally competitive pharmaceuticals industry in Australia.

    In respect of this merit criterion, applicants could address the following factors:

            (a) how the applicant's proposed R&D activities will enhance or strengthen the Australian industry's capabilities (for example, by filling a gap in the value chain, developing expertise, or introducing new skills, knowledge, technologies or techniques);

            (b) the extent that the applicant's proposed R&D activities will bring benefits to Australia through existing and new partnerships and collaborations;

            (c) the utilisation and development of Australian competitive strengths and capabilities, resources and inputs, including Australian-developed intellectual property in undertaking the proposed projects;

            (d) the extent to which there is potential for benefit to other industries as a result of the company's introduction of new transferable skills, knowledge, technologies or techniques;

            (e) the extent to which there is likely to be future licensing and other revenues from the proposed portfolio of activities;

            (f) the extent to which the applicant, in undertaking its proposed R&D, will contribute to improved health outcomes for Australians;

            (g) the extent to which the applicant is committed to doing business in Australia in the longer-term, including by reference to the applicant's long-term R&D and business strategy in Australia;

            (h) how participation in P³ secures Australia's position as a provider of world-class pharmaceutical R&D, through, for example, the establishment of an R&D hub in Australia; and

            (i) whether the applicant's R&D facilities in Australia will be responsible for a higher proportion of its global R&D as a result of participation in the Program.

    These factors should not be considered exhaustive nor will they all be applicable to all applicants.  Applicants are also welcome to provide further relevant evidence to support their